Skip to main content
Contact Us
Subscribe
E-Edition
52°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Entertainment
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Biogen Inc.
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
March 22, 2023
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
March 16, 2023
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
March 08, 2023
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
March 05, 2023
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
February 27, 2023
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
February 06, 2023
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
SAGE
Lecanemab Receives Priority Review Status in Japan
January 29, 2023
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
January 26, 2023
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
Biogen Names Priya Singhal as Executive Vice President, Head of Development
January 05, 2023
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
January 04, 2023
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
IONS
Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
December 19, 2022
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
December 09, 2022
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS
December 05, 2022
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
Biogen Names Christopher Viehbacher President and Chief Executive Officer
November 10, 2022
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
October 26, 2022
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS
October 26, 2022
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
October 17, 2022
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
July 26, 2022
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)
September 30, 2022
From
Biogen Inc.
Via
Globe NewsWire
Tickers
BIIB
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.